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Opinion statement
Local residual disease occurs in 7-13 % after primary treatment for nasopharyngeal car-
cinoma (NPC). To prevent tumor progression and/or distant metastasis, treatment is
indicated. Biopsy is the “gold standard” for diagnosing residual disease. Because late
histological regression frequently is seen after primary treatment for NPC, biopsy
should be performed when imaging or endoscopy is suspicious at 10 weeks. Different
modalities can be used in the treatment of local residual disease. Interestingly, the
treatment of residual disease has better outcomes than treatment of recurrent disease.
For early-stage disease (rT1-2), treatment results and survival rates are very good and
comparable to patients who had a complete response after the first treatment. Surgery
(endoscopic or open), brachytherapy (interstitial or intracavitary), external or stereo-
tactic beam radiotherapy, or photodynamic therapy all have very good and comparable
response rates. Choice should depend on the extension of disease, feasibility of the
treatment, and doctor’s and patient’s preferences and experience, as well as the risks
of the adverse events. For the more extended tumors, choice of treatment is more
difficult, because complete response rates are poorer and severe side effects are
not uncommon. The results of external beam reirradiation and stereotactic radiother-
apy are better than brachytherapy for T3-4 tumors. Photodynamic therapy resulted in
good palliative responses in a few patients with extensive disease. Also, chemother-
apeutics or the Epstein-Barr virus targeted therapies can be used when curative in-
tent treatment is not feasible anymore. However, their advantage in isolated local
failure has not been well described yet. Because residual disease often is a problem
in countries with a high incidence of NPC and limited radiotherapeutic and surgical
facilities, it should be understood that most of the above mentioned therapeutic mo-
dalities (radiotherapy and surgery) will not be readily available. More research with
controlled, randomized trials are needed to find realistic treatment options for resid-
ual disease.
Introduction
Treatment results of nasopharyngeal carcinoma (NPC)
have been improved by the introduction of combining
chemotherapy and radiotherapy, better radiotherapy
techniques, and enhanced imaging studies. Neverthe-
less, local failure occurs in 10 % to 30 % [1, 2]. Treat-
ment of local failure is challenging, due to the
anatomical difficult accessibility of the nasopharynx
and the high risk on therapy related complications.
Treatment options include surgery, reirradiation by ex-
ternal beam, brachytherapy or stereotactic radiothera-
py, photodynamic therapy, and chemotherapy.
Sometimes combinations are used. Many studies are
conducted, but no consensus has been reached on
the best treatment option for local failure. For early-
stage residual disease (rT1-2), a significant benefit is
found when salvage treatment is performed. Radiation
and surgical modalities have comparable response,
survival, and complication rates. For more advanced
tumors (rT3-4), the benefit of salvage treatment is less
clear, probably due to the high treatment related mor-
bidity and mortality, caused by large tumor volumes
and involvement of surrounding structures [2, 3•].
Local failure can be divided in residual or recurrent
disease. The definition of residual disease is arbitrary.
Usually it is defined as the confirmation of disease oc-
curring within 6 months after treatment. When disease
is found after these 6 months, provided that previous
complete response was seen, it is defined as recurrent
disease. The incidence of residual disease is 7-13 % [4–
12]. In reviews of treatment options for local failure of
NPC, residual or recurrent disease rarely is distin-
guished. Articles that have made this distinction found
that residual disease responds better than recurrent
disease to the modalities based on reirradiation
[13, 14]. This is controversial, because studies on
reirradiation for recurrent head and neck tumors
have shown that a longer interval between the initial
and the second course of radiation is an indepen-
dent prognostic factor for a more beneficial treat-
ment outcome [15]. In view of that, there might
be a difference in the preferential treatment for re-
sidual compared with recurrent NPC.
We would like to emphasize the need to study re-
sidual disease, because we believe, based on our expe-
rience in Indonesia, that residual disease is an
underexposed problem [16••, 17•]. The reason for
the good results of residual disease compared with re-
current might be derived from insufficient primary
treatment. In many countries where NPC has high in-
cidences (like Tunisia, Algeria, Philippines, Indonesia),
access to high-standardmedical care is not readily avail-
able for everyone [18•]. Unfortunately, scientific publi-
cations from these regions that could expose these
problems also are lacking. Reasons for the high inci-
dence of persistent disease are that treatment is fre-
quently given by old fashioned and/or poorly
maintained equipment, besides 3-D conventional ra-
diotherapy or IMRT and also enhanced imaging facili-
ties, such as MRI and PET scan are in most hospitals
not available. In addition, studies in Indonesia revealed
that patients have more advanced-stage disease due to
delay in diagnosis and long intervals to treatment due
to waiting lists for radiotherapy [16••]. Also, the overall
treatment time is prolonged due to problems, such as
unreliable equipment, public holidays, and poor phys-
ical condition of the patients [19]. For these patients, it
is of great importance to find realistic treatment options
for residual NPC. Additional treatment could in these
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patients be considered as a boost after the primary treat-
ment aiming for a complete response.
To our knowledge, no review on solely residual dis-
ease has been published. The focus of this review is on
the treatment of local residual disease after primary ra-
diation or chemoradiation, given with curative intent.
Indication, treatment procedure, outcome, and side ef-
fects will be compared per modality.
Treatment
& Treatment of primary NPC consists of full dose external beam radi-
ation (66-70 Gy) to the nasopharynx and positive neck nodes and a
prophylactic dose of 40-50 Gy to the rest of the neck. Chemotherapy
can be administered as neoadjuvant, concurrent, or adjuvant. The
current standard treatment is radiotherapy for stage I and concurrent
chemoradiotherapy for Stage II-IVb. Stage IVc is treated with only
palliative intent (AJCC 2010).
& After radiotherapy, it is hard to distinguish postirradiation effects
from residual tumor by endoscopy and CT scan and/or MRI. PET
may distinguish better, but biopsy remains the “gold standard.” To
date, there is much interest on Epstein-Barr Virus (EBV) markers for
NPC, because the majority of NPC is EBV related, especially in en-
demic countries. Elevated DNA load and antibodies for EBV in blood
are correlated to the presence of NPC and valuable in detecting NPC
recurrences [20]. Unfortunately, the positive predicting value of ele-
vated levels directly after therapy is limited. Besides, these tests do
not give information on the location of the tumor. Hence, they are
not yet adequate in confirming who needs additional treatment for
local failure. A brush for measuring EBV load in the nasopharynx
might have more potential for confirming local residual disease [21,
22]. However, more research for its use as a determinant for giving
adjuvant treatment is needed.
& The optimal length of the interval to retreatment of NPC is a topic of
debate. Some investigators advocate treating as soon as possible in
order to prevent progression and dissemination, others advocate
waiting for at least 10 weeks, because late histological regressions
might occur. Kwong et al. [23] studied the histological regression and
performed serial posttreatment-nasopharyngeal biopsies in 803 pa-
tients. After treatment, 77 % of the biopsies were negative, 4 %
regressed within 5 weeks, and 12 % regressed between weeks 5 and
12. In 7 %, the biopsies remained tumor-positive at 12 weeks. Hence,
70 % of the posttreatment-positive biopsies regressed within
12 weeks without additional treatment. A curve, containing the
percentages of regression per posttreatment week, reaches a plateau
after the tenth week, indicating that after week 10 the chances for
spontaneous regression diminish and justify additional treatment.
When interpreting treatment results for persistent disease, one
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should keep in mind these findings, because results might be biased
by the spontaneous regression of late-responding tumors.
& Kwong et al. also studied the tumor control rates for the different
regression patterns [23]. Early regression was defined as negative
biopsy before the fifth week, late regression as regression between
weeks 5 and 12, and persistent disease as a positive biopsy at
12 weeks. There was no difference between the late and early re-
gression in 5-year local control rate (82 % vs. 77 %), regional and
distant metastasis-free rate (69 % vs. 72 %) and overall survival
(75 % vs. 79 %). This justifies a wait-and-see policy for positive bi-
opsies until the tenth week. Patients with persistent disease at
12 weeks had significantly lower local control rate (40 %), regional
and distant metastasis-free rate (47 %), and overall survival (54 %).
Hence, additional treatment for this group is indicated.
& Different treatment modalities can be used for the treatment of re-
sidual NPC. The extent of the disease, comorbidity of the patient,
initial treatment, availability of treatment modalities, and experience
of the treating surgeon and radiation oncologist are decisive in the
choice of treatment.
Radiotherapy
& The choice for reirradiation in recurrent or persistent head and
neck tumors after a previous full radiation course should be
considered carefully. A higher cumulative radiation dose gives
more chance on tumor control but more risk to complication.
Moreover, a shorter interval between previous radiation, larger
tumor volume, and poor clinical condition are associated with a
worse outcome and more complications. Only for a limited pa-
tient group, who have no other curative options or as adjuvant
treatment to surgery, reirradiation of the head and neck can be
considered [24, 25]. For NPC, different irradiation modalities
have been used, such as brachytherapy, stereotactic radiation, and
external beam reirradiation. Contrary to other head and neck
tumors and recurrent NPC, the results of reirradiation for residual
NPC are quite good.
Procedures
Brachytherapy
& Brachytherapy delivers a high radiation dose to the target area with a
steep dose curve to avoid a high dose to surrounding tissue.
Brachytherapy has been used for NPC since the 1920s [13]. For re-
sidual NPC, an applicator (intracavitary brachytherapy (ICB)) or
interstitial gold implantations have been used. Studies on solely re-
sidual disease are limited. Table 1 shows the results and side effects
of these studies.
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Intracavitary brachytherapy
& The advantage of intracavitary brachytherapy (ICB) is that the
applicator can be inserted under local anesthesia. Tumors con-
fined to the mucosal or submucosal nasopharynx are suitable.
This treatment is not indicated for tumors extending to the
parapharyngeal site, base of skull, or oropharynx. To prevent
failure due to geographical miss, sophisticated imaging, such as
CT scan or MRI, should be performed.
& Teo et al. published one of the largest series of ICB for residual NPC
[7]. Administration of 24 Gy/3 fractions/15 days to 71 patients with
a positive biopsy after 6 weeks resulted in a complete response in
93 %. Five-year local control (LC) of these patients was 74 % and
overall survival (OS) was 68 %.
& Law et al. [26] treated 23 patients with ICB for residual (rT1-2) dis-
ease, using 25-50 Gy in 4-7 days. Complete response (CR) was
obtained in 97 % and the 5-year LC was with 90 %.
& Leung et al. [6] treated 87 patients with ICB (22.5-24 Gy in
3 weeks). If the nasopharynx was suspected on endoscopy, a
biopsy was performed at a median of 6 weeks posttreatment. The
results were compared to patients who had a complete response
after primary treatment with EBRT only. Patients treated for early-
stage residual disease had equal local control rates as patients
who had a complete response after primary EBRT (80-95 %). The
authors postulated that ICB might be effective to compensate for
inadequate primary treatment. Patients who had advanced T stage
at primary diagnosis did worse both with respect to local control
and survival. A substantial number of these patients might still
have had extension outside the nasopharynx. A different treat-
ment modality might have been more suitable for this group.
Hence, these results confirm the benefit of restaging before
retreatment.
Brachytherapy gold implant
& Kwong et al. [13] used brachytherapy with radioactive gold
implants for residual disease. Small lesions with clear bound-
aries or lesions situated on one side of the nasopharynx were
suitable. Lesions in the eustachian tube or extending into the
nasal cavity were not suitable, because the implants cannot be
attached firmly to thin mucosa. Treatment was not performed
within 3 months after primary radiation. Gold implants were
inserted under general anesthesia, via an incision through the
soft palate. A dose of 60 Gy at 0.5 cm away from the source was
prescribed. The median number of implants was six. Patients
were discharged on the fourth postoperative day. Persistent
disease did better than recurrent disease (LC 87 % vs. 63 %, OS
79 % vs. 54 %). Some patients with parapharyngeal extension
or skull base erosion also were treated, despite the fact they
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were not strictly eligible for this treatment. However, these pa-
tients got the benefit of the doubt, because confirmation of the
disease by biopsy was not possible at these sides. As expected,
these patients did worse than patients with disease confined to
the nasopharynx on 5-year LC (52 % vs. 72 %).
Stereotactic radiation
& Since 1991 stereotactic radiation (SRT) is used in the treatment of
local failure of NPC [27]. SRT can be delivered as a single dose or in
multiple fractions.
& Most studies are retrospective and patient selection often is based on
the unsuitability for brachytherapy or nasopharyngectomy. Tumors
suitable for SRT can be lesions with skull base erosion or orbit in-
vasion or intracranial extension. The CR and 3-year LC are up to
100 % for T1-3 disease [28•]. In Table 1, the studies involving re-
sidual disease are shown.
& Fractionated versus single fraction stereotactic radiation; based
on the biological principles of radiation, fractionated treatment
would provide a favorable therapeutic ratio with fewer side ef-
fects. Chua and Wu et al. compared their treatment results in a
matched cohort analysis [29]. Patients were matched individu-
ally for the following prognostic factors: persistent versus re-
current disease, rT stage, and tumor volume. Fractionated SRT
had a better outcome in 3-year local failure-free survival, espe-
cially for recurrent disease and tumors growing beyond the na-
sopharynx (T2-4). The subgroup analysis for persistent disease
showed no significant benefit for either fractionated or single
fraction SRT.
External beam reirradiation
& Yan et al. [11, 30] conducted two large studies concerning the
treatment of residual disease by EBRT. The first study was retro-
spective and consisted of 182 patients (20-50 Gy); the second
was a prospective study with 78 patients (20 Gy, 4 Gy/fr, 2 fr/
week). Both studies involved patients treated and untreated for
residual disease and found that treated patients did better with
respect to LC and OS (Table 1). In the prospective study, these
patients were compared with patients who had a complete re-
sponse after the initial treatment. There was no difference in 3-
year LC (96 % and 94 %) for the initial complete responders and
the salvage group. The observation group with a positive biopsy
did significantly worse (LC 64 %). OS was similar in all groups.
Although there might be a bias, because biopsy was taken 10-
14 days after initial treatment, these studies emphasised the need
for treatment of residual disease.
& Intensity-modulated EBRT (IMRT) has good results for the treat-
ment of recurrent disease (5-year LC of 85-66 % and OS of 71-
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30 %, depending on rT stage) [31, 32, 33•]. Unfortunately, most
studies have a gap interval to reirradiation of more than
6 months. Because good results of other reirradiation techniques
for residual disease have been achieved, IMRT also has the po-
tential to be a good treatment for residual disease, but studies
have to confirm this.
Comparison between modalities
ICB vs 3D-RT In 2004, Zheng et al. [5] retrospectively compared the outcome of 3D-
RT and ICB for residual disease. Residual disease was confirmed by
biopsy 2-8 weeks after initial treatment. ICB was given to 63 patients
(15-30 Gy, depending on the gap period of radiation, 5-6 Gy/fr, 2 fr/
week). Staging was performed at diagnosis only. In the 3D group, 54
patients were included, CT imaging was performed for restaging, and
all rT stages were included. The target volume was the tumor plus 5-
mm margin. Depending on the gap period, a dose of 16-38 Gy was
given (2 Gy/fr, 1 fr/day). The 5-year overall survival and local failure-
free survival for the 3D and the ICT groups were 65 % vs. 56 % and
89 % vs. 76 % (not significant). Subgroup analysis showed that initial
T1-2 did better than T3-4 for both groups (LC 990 % vs. 56-84 %). For
initial T1-2, no preferential treatment was found. For T3-4 tumors, the
local failure-free survival was significantly better for the 3D group
(84 % vs. 61 %).
ICB vs SRT Yau et al. [4] retrospectively compared ICB with SRT for residual
disease; 24 were treated by ICB (10-24 Gy 2 fr/week) and 21 with SRT
(entire nasopharyngeal mucosa and gross residual tumor within 3-
5 mm margin, 15 Gy). The initial diagnosis was T3-4 in 21 % of the
ICB group and in 43 % of the SRT group. The time interval to
retreatment was 8-16 weeks. ICB and SRT had similar complete re-
sponse rates (96 % and 95 %). Treatment results were compared to
patients with a complete response after the primary treatment and an
identical 3-year overall survival (82-83 %) was found. Local control
rate was 84 % in the initial complete responders, 71 % in the ICB
group, 82 % in the SRT group, and 43 % in the group of untreated
patients with residual disease. Only the SRT group achieved local
control rates comparable with the complete responders, despite the
higher frequency of T3-4 disease at initial diagnosis. The incidence of
grade 3-4 side effects were similar in the retreated patients and the
group without salvage treatment.
Complications
& Adverse events commonly are seen after reirradiation and are the
limiting factor in treatment (Table 1). After ICB, 12-28 % experience
severe adverse events. Nasopharyngeal necrosis (4-10 %), endocrine
dysfunction (6-9 %), hearing loss (6-30 %), and cranial neuropathy
(1-12 %) are frequently seen [4–7, 26]. Law et al. [26] all gave the
highest radiation dose and had the best LR rates for ICB; unfortu-
nately they also had the most severe adverse events, e.g., temporal
lobe necrosis was seen in 9 % of the treated patients. Leung, Zheng,
and Yau et al. [4–6] compared patients who had ICB with patients
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who got no additional treatment and found no significant differ-
ences in the number of adverse events. Brachytherapy with gold
implants have comparable adverse events to ICB. Headache fre-
quently is seen and related to the number of implants. Fistulas were
seen in 50 % of the patients, but by changing the palatal closing
procedure into three layers they were not seen anymore. SRT caused
brain necrosis in 9-25 % and severe haemorrhage in 6-8 %, in some
cases leading to death [29, 34]. Fractionated SRT should in the-
ory give less adverse events, but the comparison made by Chua
and Wu showed no differences with single fraction SRT. Risk for
massive hemorrhage is present when there is tumor extension to
the cavernous sinus, or retropharyngeally to the carotid sheet, or
when there is mucosal necrosis, tumor progression, or carotid
aneurysm. If the tumor encases the cavernous sinus or carotid
artery, single-dose SRS should be avoided, but also multifraction
SRT should be used very carefully [29]. Yan et al. [11] gave EBRT
for residual disease and reported encephalomyelitis in 17 %
compared with 6 % in the patients who only received primary
EBRT only (pG0.05). Comparable incidence rates of grade 3-4
side effects are mentioned after 3D-RT by Zheng et al. [5]. They
also compared the results with patients who received primary
EBRT only and found no significant difference in the incidence of
side effect. Although the incidence of cranial neuropathy merits
caution (7 % in the retreated group vs. 3 % in the primary EBRT-
only group). IMRT should in principle have fewer side effects
than 2D and 3D EBRT. Unfortunately, no studies on residual
disease only have been conducted.
Special points
& Brachytherapy, SRT, and EBRT are all suitable modalities for small
residual lesions with comparable control and complication rates.
When the tumor extends outside the nasopharynx, SRT or EBRT is
preferable to brachytherapy. Based on the experience in recurrent
disease, IMRT can be very effective in treating rT3-4 lesions, with
acceptable side effect. Nevertheless, because residual disease has the
highest incidence in regions where advanced techniques are not
available and waiting lists for conventional EBRT exist, these treat-
ment options are not realistic for these regions. For instance, in In-
donesia 0.13 radiation units per 1,000,000 inhabitants are available
compared with 2.5-5.5 units in European countries [35, 36]. In ad-
dition, in the countries with a high incidence of residual NPC often
MRI facilities are not present, which is important in deciding the
boundaries between tumor margins and healthy tissue to prevent
side effects and have adequate tumor margins. These issues represent
the problems when treating residual disease and the need to search
for alternative and realistic options.
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Surgery
Procedure
& Most experience with nasopharyngectomy comes from countries
with a very high incidence of nasopharyngeal carcinoma and with
high standard medical care, such as China. Nasopharyngectomy can
be performed by different approaches. The techniques are challeng-
ing and therefore should be performed by experienced hands only.
Surgery can only be curative if the tumor mass is radically removed,
hence there can not be intracranial extension, invasion of the base of
the scull, or carotid artery involvement. Recently, more research on
endoscopic surgery is performed, with promising results.
& The maxillary swing is an anterior-lateral approach [37•]. By a
midfacial incision, extending over the mucosal of the hard palate,
and osteotomies on the anterior maxilla, zygomatic arch, and hard
palate, the maxilla on the side of the tumor can be swung laterally to
expose the nasopharynx. One-sided tumors, with extension to lateral
are the ideal tumors for this method. Extension to the contralateral
side or oropharynx are less ideal. If there is extension or lymph node
involvement in the parapharyngeal space, this also can be resected.
Caution should be taken on the carotid artery. A free flap can be used
when the base of the skull or the carotid artery is exposed.
& With the anterior approach, the midfacial degloving procedure, the
maxilla is divided on both lateral walls and the nasopharynx is exposed
from the front. Tumors in the midline and with only minimal lateral
extension are best suited for this method, which is advantageous is that
there is no facial incision and that the soft palate remains functional.
& The nasopharynx also can be entered from inferior, the transpalatal
approach, whereby the palate is split, with or without a mandibular
swing depending on the opening of the mouth. Tumors extending to
the inferior nasopharynx or oral cavity with minimal extension to the
sides are suitable for this method [38].
& Unfortunately, to our knowledge, no study has been published that
included only persistent disease. Vlantis et al. [38] and Wei at al.
[37•] both included residual disease patients in their studies
without making a clear distinction between recurrent and residual
disease. Both studies mention briefly that there were no differ-
ences between residual and recurrent disease with respect to local
control or survival. In Table 2, results are shown for residual and
recurrent disease together. In the following part, these studies will
be outlined.
& Wei et al. [37•] performed the maxillary swing with curative intent
on 246 patients, of which 37 had persistent disease. Patients with
erosion at the skull base or invasion of the carotid artery were not
included. During surgery, frozen sections were used. Radical margins
were achieved in 78 % and a 5-year LC of 75 %.
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& Vlantis et al. [38] retrospectively reviewed80patients (14 residual disease),
all treated with curative intent. The majority (95 %) had rT1-2 stage. The
transpalatal, the maxillary swing, and the midfacial degloving approach
were compared. Of the rT1-2 tumors, clear pathological margins were
achieved in 51 %, close margins in 18 %, and 31 % had positive margins
(with no differences between the approaches). If resection margins were
positive, patients were treatedwith brachytherapy. The 5-year local control
rate for rT1-2was significantly better for themaxillary swing approach than
the facial degloving approach (88%vs. 50%). Because of the retrospective
character of this study, theremight have been a bias in tumor selection for
both approaches. Survival was equal for the three different approaches.
& Recently, endoscopic surgery is introduced. Chen et al. [39•] treated
37 patients with tumors confined to the nasopharyngeal cavity, nasal
septum, superficial parapharyngeal space, or the base of the sphe-
noid sinus. Radical margins were achieved in 97 %. During follow-
up, no recurrences were seen for the rT1, but 29 % of the tumors with
parapharyngeal extension recurred. The authors concluded that the
distance between the tumor and the carotid artery should be 91 cm
to achieve an adequate tumor margin.
Complications
& Wei et al. [37•] reported no mortality. Hospital admission ranged
from 6 days to 4 months (median 13 days). Carotid artery bleeding
Table 2. Treatment results of surgery for recurrent and residual disease
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Endoscopic 37 T1-3 97 86 (2 yr) 84 (2 yr) No severe side
effects
N, number of patients; CR, complete response; DFS, disease-free survival; OS, overall survival; LPFS, local progression-free survival
*No intracranial, skull base, or carotid extension. Most tumors were G2 cm
**Only rT1-2 and including the “clear and close” margins. The authors do not explain the meaning of this term
486 Head and Neck Cancer (JB Vermorken, Section Editor)
was seen in three patients. Palatal fistula were seen in 20 % and only
occurred in patients with a midline mucosal incision. Only 6 (2 %)
patients needed surgical repair. Trismus G2 cm was seen in 21 %.
Vlantis et al. [38] did not describe side effects. Chen’s patients were
discharged after 5 days. No severe complications were seen [39•].
Special points
& Positive resection margins and large tumor volume adversely influ-
ence local control and overall survival. Additional treatment with
chemotherapy or radiation should be considered for these cases.
Frozen sections are advisable during surgery. Before surgery, the
surgeon must carefully estimate the likelihood of adequate resection
margins. Tumors with intracranial extension or carotid artery in-
volvement are not resectable [37•, 38, 39•].
Photodynamic therapy
Procedure
& Photodynamic therapy (PDT) for NPC is based on the intravascular
injection of a photosensitizing drug. The tumor is then illuminated
with a nonthermic laser, which leads to the production of active
oxygen radicals, eventually causing local cell death. The effective
treatment depth of PDT with second-generation photosensitizers is
10 mm. With a special applicator, the nasopharynx can be illumi-
nated uniformly with protection of the soft palate. Usually one
treatment is adequate, which can be performed in an outpatient
clinic under local anesthesia. Because there is no cumulative effect,
PDT can be repeated. The procedure is easy to learn and does not need
expensive equipment. These advantages make this modality very suit-
able for hospitals with limited radiation or surgery facilities (Table 3).
& Nyst et al. [17•] treated 22 patients with temoporfin (second-gen-
eration photosensitizer) mediated PDT in Indonesia. They did not
Table 3. Treatment results of photodynamic therapy for residual disease




Recurrent T stage CR DFS OS Side effects
Nyst (2012)
[17•]
PDT 22 (21 residual) T1/2 G10-mm depth 100* 55 (3 yr) Grade 3: Headache 32 %,














PDT 1 T4 100 (5 yr)
CR, complete response; DFS, disease-free survival; OS, overall survival
*Only 17/22pts had tumor evaluation, all had CR
**One patient had complete response, this patient also received chemotherapy
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make a distinction in therapy response between residual and recur-
rent disease, but only one patient had recurrent disease. All of the 17
evaluable patients had tumor-negative biopsies after PDT and the
overall 3-year survival was 55 % (27 % died related to NPC).
& Kulapaditharomet al. [40] and Lofgren et al. [41] used hematoporphyrin
(first-generationphotosensitizer)mediatedPDTand alsohad a complete
response in all patients with T1-2 disease and a thickness less than 1 cm
(n=11). Patients with more extended disease had a partial response.
& T3-4 tumors are treated with a palliative intent only, because com-
plete illumination of the tumor is in the majority not feasible.
Nevertheless, treatment results are promising. In a case report, an
intracranial extended tumor was treated by PDT and after 5 years this
patient is still alive in good condition with no evidence of disease
[42]. Also, Kulapaditharom’s patients with T3-4 (n=7) had consid-
erable tumor regression of which five are still alive at 9, 16, 23, 37,
and 40 months [40].
Complications
& In theweeks after the injection, the patient can gradually return tonormal
daylight exposure. Headache (grade 3) was seen in 33 % in Nyst’s study
and disappeared in all patients. Kulapaditharom et al. did not describe
the side effects. The patients described by Lofgren et al. all had headache,
which was relieved by ordinary analgesics and disappeared at 3-
8 months. Furthermore, middle ear effusion and tinnitus (grade 1-2)
were frequently seen side effects. Hemorrhages were not reported.
Special points
& Nyst’s study reveals the high incidence of residual disease in Indonesia,
whereNPC is one of themost frequent cancer types andwhere only limited
access to radiotherapy and surgery facilities is available. NPC has a high
incidence in many more countries where equal or even less facilities are
available, such as North Africa or the remote regions in China. This stresses
the need for more studies on residual disease and treatment modalities,
which are easy to perform, low priced, and have a low complication rate.
Chemotherapeutic and molecular treatment
& Because small, local, residual lesions can be treated with good cu-
rative prognosis, chemotherapeutic and molecular regiments are only
indicated when the lesions are too extended for surgery, brachy-
therapy, PDT, external beam, or stereotactic radiation. These pallia-
tive intent treatments fall beyond the scope of this article and will be
discussed only briefly. Chemotherapeutic agents can be used in
combination with the other modalities or as a single modality. NPC
is sensitive to cisplatin-based regimens, with an overall response rate
in patients with recurrent disease between 50 % and 80 %, a median
time to progression of 5-11 months and a median survival of 12-
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20 months [43–46]. Because patients with residual disease just
finished treatment with cisplatin, the preferential choice might be a
nonplatinum compound, such as a taxane, gemcitabine, or
capecitabine. As monotherapy, these drugs induce response rates be-
tween 23%and48% [3•, 47•, 48, 49].More recently, studies have been
conducted withmonoclonal antibodies against epithelial growth factor
(EGFR), although after chemotherapy failures. The results are not
very satisfactory, with overall response rates of 11% and stable diseases
in 20-48 % for a limited period of time. A phase II study with the EGFR
inhibitor gefitinib, after two lines of chemotherapy, in 19 patients with
recurrent or metastatic NPC, resulted in no objective responses [50].
Also studies using EBV as target are conducted [51]. All studies included
patients with failure on sides other than local, so the use of chemo-
therapy for isolated local failure has not been well studied yet.
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